Research
Final trial results show promising long-term survival with lenvatinib plus pembrolizumab in advanced thymic tumors
The Brief
- Final results from the phase 2 PECATI clinical trial were reported.
- The trial tested lenvatinib plus pembrolizumab in previously treated advanced B3-thymoma and thymic carcinoma.
- The reported outcomes are encouraging long-term survival figures for the combination.
Why it matters
It provides long-term survival data for a combination therapy in rare, hard-to-treat thymic tumors, where evidence is limited.
Who’s affected
- oncologists and patients with advanced thymic tumors
- clinical researchers in thymic malignancies
- #oncology
- #thymic tumors
- #immunotherapy
- #clinical trial
- #lenvatinib
- #pembrolizumab
Final results from the phase 2 PECATI clinical trial demonstrate encouraging long-term survival outcomes with the combination of lenvatinib and pembrolizumab in patients with previously treated advanced B3-thymoma and thymic carcinoma.
Timeline
Final results from the PECATI phase 2 trial reported by Medical Xpress
Medical Xpress - latest medical and health news stories
Final trial results show promising long-term survival with lenvatinib plus pembrolizumab in advanced thymic tumors